Anthony F. Purchio

Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA.

Numira, Inc. develops and provides molecular imaging technologies for scientific discovery and drug development. Its products include AltaBlu Prime, AltaNexus and AltaViewer. The firm operates as a contract research organization, which provides imaging services for disease research, drug discovery, and pre-clinical studies in animal models. The company services include 3D oncology cell screening, histology, image analysis and imaging. Its therapeutic areas such as CNS, bone, pulmonary, oncology, and inflammation provide extensive value for many researchers. Through the combination of novel software technologies and imaging capabilities, Numira provides clients with an unmatched array of pre-clinical services for research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other therapeutic areas. Numira was founded in 2005 by Michael A. Beeuwsaert and Charles Keller and is headquartered in Salt Lake, UT.